Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Will Teva's Deal With FTC Change Future Patent Litigation Settlements?

Feb 22 2019

• By Brenda Sandburg

Silhouette woman to jump over obstacles over precipice between rocky mountains A Step to success at background sunset pastel.

Related Content

Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits

Jun 24 2013

Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals

Feb 21 2019

Impax Defeats FTC Pay-For-Delay Complaint, Helped By Status As Sole Marketer Of Generic Opana ER

May 21 2018

Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition

Nov 09 2017

Related Companies

Teva Pharmaceutical Industries Ltd.

Cephalon, Inc.

Allergan plc

AbbVie Inc.

Teva Pharmaceutical Industries Ltd.

Amneal Pharmaceuticals, Inc.

Endo, Inc.

Schering-Plough

Additional Topics

United States Generic Drugs Legal Issues Intellectual Property Policy BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window